Furthermore, in Fang et al.'s report, camrelizumab (anti-PD-1 antibody) monotherapy combined with chemotherapy has made promising progress in the first-line treatment of recurrent and metastatic NPC 5. Here, PDCD1 is linked to nasopharyngeal carcinoma.